Premium functions are now FREE OF CHARGE due to the modification of the investment data Data developments may cause some parts work incorrectly Incorrect sections - Financial statements, Earnings upcoming dates and calendars Please take our apologise. It will be fixed soon

GILD - Gilead Sciences, Inc.

IEX Last Trade
78.98
-0.470   -0.595%

Share volume: 6,204,270
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%
$79.45
-0.47
-0.59%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 48%
Dept financing 24%
Liquidity 19%
Performance 47%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.97%
1 Month
1.22%
3 Months
24.80%
6 Months
12.26%
1 Year
9.12%
2 Year
42.29%
Key data
Stock price
$78.98
P/E Ratio 
93.40
DAY RANGE
$78.60 - N/A
EPS 
$0.84
52 WEEK RANGE
$61.32 - $85.05
52 WEEK CHANGE
$0.11
MARKET CAP 
98.354 B
YIELD 
3.76%
SHARES OUTSTANDING 
1.245 B
DIVIDEND
$0.77
EX-DIVIDEND DATE
06/14/2024
NEXT EARNINGS DATE
11/07/2024
BETA 
0.21
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$5,367,311
AVERAGE 30 VOLUME 
$5,445,135
Company detail
CEO: Daniel O'Day
Region: US
Website: https://www.gilead.com/
Employees: 17,000
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

Recent news